Janux Therapeutics’ (JANX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They currently have a $100.00 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 85.46% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Scotiabank lowered their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Finally, UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, Janux Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Price Performance

JANX stock opened at $53.92 on Thursday. Janux Therapeutics has a one year low of $5.65 and a one year high of $65.60. The stock has a market cap of $2.81 billion, a PE ratio of -46.09 and a beta of 3.52. The firm has a 50 day simple moving average of $49.02 and a two-hundred day simple moving average of $46.39.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.95%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, research analysts expect that Janux Therapeutics will post -1.18 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the sale, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The shares were purchased at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the transaction, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 420,610 shares of company stock valued at $19,288,666 in the last three months. 29.40% of the stock is currently owned by company insiders.

Institutional Trading of Janux Therapeutics

Several institutional investors have recently bought and sold shares of JANX. Logos Global Management LP grew its position in Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Janux Therapeutics during the 1st quarter valued at about $20,420,000. Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the last quarter. Altitude Crest Partners Inc. purchased a new stake in shares of Janux Therapeutics during the 1st quarter valued at about $7,278,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $5,715,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.